TherapeuticsMD Inc. Stock Outperforms Competitors On Strong Trading Day
TherapeuticsMD Third Quarter 2024 Earnings: US$0.049 Loss per Share (Vs US$0.13 Loss in 3Q 2023)
Therapeutics MD GAAP EPS of -$0.05
セラピューティクスエムディー | 10-Q:Q3 2024 四半期報告書
セラピューティクスエムディー | 8-K:セラピューティクス/SMDが2024年第3四半期の決算を発表
Press Release: TherapeuticsMD Announces Third Quarter 2024 Financial Results
TherapeuticsMD And 2 Other Stocks Under $2 Executives Are Buying
セラピューティクスMD | 10-Q:Q2 2024 四半期報告書
セラピューティクスMD | 8-K:セラピューティクス/SMDが2024年第2四半期の決算を発表
TherapeuticsMD 2Q License Rev $234,000
TherapeuticsMD 2Q Loss Cont Ops 9c/Shr
U.S. Menopause Market Trends Analysis Report 2024-2030 Featuring Pfizer, Novo Nordisk, TherapeuticsMD, Bayer, AbbVie, Pure Encapsulations, and PADAGIS
Nektar, Verastem Among Healthcare Additions in Russell Microcap; Assertio, Sangamo Removed
セラピューティクスMD | 10-Q:Q1 2024 四半期報告書
セラピューティクスMD | 8-K:セラピューティクス/SMDが2024年第1四半期の決算を発表
TherapeuticsMD Q1 EPS $(0.07) Up From $(0.24) YoY
TherapeuticsMD 1Q Cont Ops Loss/Shr 7c >TXMD
Press Release: TherapeuticsMD Announces First Quarter 2024 Financial Results
Therapeutics MD Reports FY Results
TherapeuticsMD: Evaluation of Strategic Alternatives Continues >TXMD